Yasir Al-Wakeel joined Kronos Bio as Chief Financial Officer and Head of Corporate Development in 2020. Prior to joining Kronos Bio, Yasir was Chief Financial and Strategy Officer at Neon Therapeutics, where he played a key role in the company’s public and private financings, as well as its eventual sale to BioNTech. Before Neon, he was Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, where he helped shape and execute the company’s refocused business strategy, culminating in a $1 billion asset sale to Ipsen. Earlier in his career, Yasir served in senior roles in equity research and corporate finance at Credit Suisse, where he was involved in more than $30 billion in strategic and financial transactions with an emphasis on biotechnology. Yasir began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom. Yasir is a member of the board of directors of MaxCyte, Inc. He received his BM BCh (Doctor of Medicine and Surgery) from Oxford University and an M.A. in theology from Cambridge University.